Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
08:32 ET | 701 | 41.52 |
08:34 ET | 1631 | 41.47 |
08:52 ET | 1400 | 41.36 |
08:54 ET | 100 | 41.515 |
08:57 ET | 100 | 41.34 |
09:19 ET | 100 | 41.41 |
09:21 ET | 100 | 41.49 |
09:24 ET | 100 | 41.47 |
09:33 ET | 100 | 41.485 |
09:35 ET | 100 | 41.485 |
09:42 ET | 100 | 41.54 |
09:44 ET | 1380 | 41.51 |
09:46 ET | 200 | 41.48 |
09:50 ET | 200 | 41.47 |
09:51 ET | 1300 | 41.35 |
09:55 ET | 200 | 41.38 |
09:57 ET | 1640 | 41.43 |
10:00 ET | 200 | 41.335 |
10:04 ET | 49700 | 41.25 |
10:06 ET | 900 | 41.13 |
10:08 ET | 900 | 40.905 |
10:09 ET | 1320 | 40.95 |
10:11 ET | 400 | 40.82 |
10:13 ET | 600 | 41.1 |
10:15 ET | 100 | 41.04 |
10:18 ET | 300 | 41.17 |
10:20 ET | 100 | 41.18 |
10:22 ET | 100 | 41.17 |
10:27 ET | 300 | 41.27 |
10:29 ET | 300 | 41.26 |
10:31 ET | 300 | 41.175 |
10:33 ET | 100 | 41.18 |
10:36 ET | 400 | 41.13 |
10:40 ET | 100 | 41.08 |
10:42 ET | 200 | 40.89 |
10:44 ET | 100 | 40.87 |
10:49 ET | 100 | 40.86 |
11:00 ET | 100 | 40.885 |
11:03 ET | 400 | 40.98 |
11:05 ET | 500 | 40.88 |
11:25 ET | 220 | 41.0352 |
11:27 ET | 300 | 40.86 |
11:32 ET | 700 | 40.72 |
11:34 ET | 400 | 40.66 |
11:36 ET | 100 | 40.725 |
11:41 ET | 1297 | 40.775 |
11:43 ET | 700 | 40.68 |
11:50 ET | 2330 | 40.715 |
11:56 ET | 706 | 40.77 |
11:59 ET | 1293 | 40.85 |
12:03 ET | 1100 | 40.835 |
12:06 ET | 100 | 40.845 |
12:10 ET | 2929 | 40.925 |
12:12 ET | 100 | 40.93 |
12:14 ET | 100 | 40.94 |
12:15 ET | 100 | 40.87 |
12:19 ET | 1500 | 40.89 |
12:21 ET | 420 | 40.85 |
12:26 ET | 720 | 40.85 |
12:28 ET | 400 | 40.875 |
12:30 ET | 300 | 40.875 |
12:32 ET | 100 | 40.875 |
12:33 ET | 246 | 40.76 |
12:35 ET | 2700 | 40.845 |
12:37 ET | 1073 | 40.785 |
12:39 ET | 100 | 40.825 |
12:42 ET | 100 | 40.825 |
12:44 ET | 467 | 40.83 |
12:46 ET | 705 | 40.79 |
12:48 ET | 300 | 40.79 |
12:57 ET | 805 | 40.81 |
01:00 ET | 200 | 40.79 |
01:02 ET | 6029 | 40.92 |
01:06 ET | 2714 | 40.9157 |
01:08 ET | 100 | 40.98 |
01:09 ET | 200 | 40.96 |
01:13 ET | 500 | 40.83 |
01:15 ET | 600 | 40.77 |
01:20 ET | 200 | 40.87 |
01:22 ET | 300 | 40.82 |
01:26 ET | 500 | 40.85 |
01:29 ET | 700 | 40.8 |
01:31 ET | 1584 | 40.83 |
01:33 ET | 400 | 40.93 |
01:36 ET | 100 | 40.94 |
01:40 ET | 200 | 40.94 |
01:47 ET | 2400 | 40.92 |
01:49 ET | 300 | 40.92 |
01:51 ET | 1980 | 40.95 |
01:54 ET | 900 | 41.05 |
01:56 ET | 600 | 41.17 |
01:58 ET | 400 | 41.2 |
02:00 ET | 600 | 41.17 |
02:02 ET | 400 | 41.2 |
02:03 ET | 200 | 41.14 |
02:07 ET | 100 | 41.135 |
02:12 ET | 100 | 41.18 |
02:14 ET | 200 | 41.18 |
02:16 ET | 14500 | 41.145 |
02:18 ET | 3282 | 41.24 |
02:20 ET | 100 | 41.24 |
02:21 ET | 338 | 41.255 |
02:23 ET | 100 | 41.255 |
02:25 ET | 611 | 41.21 |
02:27 ET | 300 | 41.21 |
02:30 ET | 519 | 41.19 |
02:32 ET | 392 | 41.175 |
02:34 ET | 1178 | 41.165 |
02:36 ET | 1500 | 41.27 |
02:39 ET | 501 | 41.301 |
02:41 ET | 1335 | 41.37 |
02:43 ET | 700 | 41.415 |
02:45 ET | 517 | 41.47 |
02:48 ET | 100 | 41.485 |
02:50 ET | 161 | 41.475 |
02:52 ET | 979 | 41.4 |
02:54 ET | 1600 | 41.45 |
02:56 ET | 1445 | 41.51 |
02:57 ET | 2569 | 41.555 |
02:59 ET | 34702 | 41.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 3.2B | -15.2x | --- |
Apogee Therapeutics Inc | 3.2B | -24.2x | --- |
Edgewise Therapeutics Inc | 3.2B | -22.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
MoonLake Immunotherapeutics | 3.0B | -51.7x | --- |
Iovance Biotherapeutics Inc | 3.4B | -6.7x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.21 |
EPS | $-2.74 |
Book Value | $12.31 |
P/E Ratio | -15.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.